NO20075278L - Fremgangsmate behandling av aktinisk keratose - Google Patents

Fremgangsmate behandling av aktinisk keratose

Info

Publication number
NO20075278L
NO20075278L NO20075278A NO20075278A NO20075278L NO 20075278 L NO20075278 L NO 20075278L NO 20075278 A NO20075278 A NO 20075278A NO 20075278 A NO20075278 A NO 20075278A NO 20075278 L NO20075278 L NO 20075278L
Authority
NO
Norway
Prior art keywords
actinic keratosis
procedure
treatment
rhenylpropyl
rhenyl
Prior art date
Application number
NO20075278A
Other languages
English (en)
Norwegian (no)
Inventor
James H Lee
Terrance L Fox
Original Assignee
Meda Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Ab filed Critical Meda Ab
Publication of NO20075278L publication Critical patent/NO20075278L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
NO20075278A 2005-03-14 2007-10-15 Fremgangsmate behandling av aktinisk keratose NO20075278L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66166105P 2005-03-14 2005-03-14
PCT/US2006/008868 WO2006099275A2 (fr) 2005-03-14 2006-03-14 Methode de traitement de la keratose actinique

Publications (1)

Publication Number Publication Date
NO20075278L true NO20075278L (no) 2007-12-10

Family

ID=36992327

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075278A NO20075278L (no) 2005-03-14 2007-10-15 Fremgangsmate behandling av aktinisk keratose

Country Status (15)

Country Link
US (1) US8354424B2 (fr)
EP (1) EP1865957A4 (fr)
JP (1) JP2008533148A (fr)
CN (1) CN101175493A (fr)
AU (1) AU2006223148A1 (fr)
BR (1) BRPI0608011A2 (fr)
CA (1) CA2602098A1 (fr)
CR (1) CR9382A (fr)
EC (1) ECSP077736A (fr)
IL (1) IL185581A0 (fr)
MX (1) MX2007011112A (fr)
NI (1) NI200700239A (fr)
NO (1) NO20075278L (fr)
RU (1) RU2007137960A (fr)
WO (1) WO2006099275A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
ES2406730T3 (es) 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
CA2540541C (fr) 2003-10-03 2012-03-27 3M Innovative Properties Company Imidazoquinolines a substitution alcoxy
CA2540598C (fr) 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines et analogues de celles-ci
JP4891088B2 (ja) 2003-11-25 2012-03-07 スリーエム イノベイティブ プロパティズ カンパニー 置換されたイミダゾ環系および方法
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
AU2005322898B2 (en) 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
US20080318998A1 (en) 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
US8658666B2 (en) 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
CA2598639A1 (fr) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Imidazonaphthyridines a substitution hydroxyalkyle
JP2008538203A (ja) 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ,インコーポレイテッド インターフェロンの生合成を優先的に誘導する方法
AU2006216798A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
EP1851224A2 (fr) 2005-02-23 2007-11-07 3M Innovative Properties Company Imidazoquinolines a substitution hydroxyalkyle
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
JP2009507856A (ja) 2005-09-09 2009-02-26 コーリー ファーマシューティカル グループ,インコーポレイテッド N−{2−[4−アミノ−2−(エトキシメチル)−1H−イミダゾ[4,5−c]キノリン−1−イル]−1,1−ジメチルエチル}メタンスルホンアミドのアミドおよびカルバマート誘導体ならびに方法
JP5247458B2 (ja) 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー ヒドロキシ及びアルコキシ置換1h−イミダゾキノリン及び方法
US8951528B2 (en) 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (fr) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. 1h-imidazonaphthyridines hydroxy et alcoxy substituées, et procédés associés
WO2008030511A2 (fr) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. 3, 4, 6, 7-tétrahydro-5h-1, 2a, 4a, 8-tétraazacyclopenta[cd]phénalènes substitués
HUE033901T2 (en) 2010-08-17 2018-01-29 3M Innovative Properties Co Formulations and formulations for lipidized immune response modifying compounds and related processes
CA2838158C (fr) 2011-06-03 2019-07-16 3M Innovative Properties Company Lieurs heterobifonctionnels comportant de segments de polyethylene glycol et conjugues modificateurs de reponse immunitaire obtenus a partir de ceux-ci
JP6415979B2 (ja) 2011-06-03 2018-10-31 スリーエム イノベイティブ プロパティズ カンパニー ヒドラジノ1h−イミダゾキノリン−4−アミン及びこれから調製された複合体
RU2495628C1 (ru) * 2012-04-18 2013-10-20 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ выбора тактики лечения актинического кератоза
CN109922748A (zh) * 2016-08-01 2019-06-21 德雷塞尔大学 用于处理皮肤病况的装置和方法
JP7197244B2 (ja) 2017-12-20 2022-12-27 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ[4,5-c]キノリン化合物

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) * 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3764681A (en) * 1970-07-08 1973-10-09 Lilly Co Eli Certain tetrazolo-(1,5-a) quinoline compounds as fungus control agents
US3917624A (en) * 1972-09-27 1975-11-04 Pfizer Process for producing 2-amino-nicotinonitrile intermediates
ZA848968B (en) * 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
ES2071340T3 (es) * 1990-10-05 1995-06-16 Minnesota Mining & Mfg Procedimiento para la preparacion de imidazo(4,5-c)quinolin-4-aminas.
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
JPH09500128A (ja) 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー イミダゾ〔4,5−c〕ピリジン−4−アミン
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
JPH09208584A (ja) 1996-01-29 1997-08-12 Terumo Corp アミド誘導体、およびそれを含有する医薬製剤、および合成中間体
JPH09255926A (ja) 1996-03-26 1997-09-30 Diatex Co Ltd 粘着テープ
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
DE69737935T2 (de) 1996-10-25 2008-04-03 Minnesota Mining And Manufacturing Co., St. Paul Die Immunantwort modifizierende Verbindung zur Behandlung von durch TH2 vermittelten und verwandten Krankheiten
PT839810E (pt) * 1996-11-04 2003-01-31 Bayer Cropscience Sa 1-poliarilpirazois como pesticidas
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
US6069149A (en) 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
DK1512685T3 (da) * 1997-12-11 2006-11-20 Minnesota Mining & Mfg Imidazonaphthyridiner og deres anvendelse til induktion af cytokinbiosyntese
JPH11222432A (ja) 1998-02-03 1999-08-17 Terumo Corp インターフェロンを誘起するアミド誘導体を含有する外用剤
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h―イミダゾピリジン誘導体
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
EP1140091B1 (fr) 1999-01-08 2005-09-21 3M Innovative Properties Company Formulations pour le traitement de la dysplasie cervicale au moyen d'un modificateur de la reponse immunitaire
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (ja) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
AU3249802A (en) 2000-12-08 2002-06-18 3M Innovative Properties Co Screening method for identifying compounds that selectively induce interferon alpha
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US7226928B2 (en) 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
WO2003020889A2 (fr) 2001-08-30 2003-03-13 3M Innovative Properties Company Procedes de maturation de cellules dendritiques plasmocytoides au moyen de molecules modifiant les reponses immunitaires
WO2003094836A2 (fr) 2001-10-12 2003-11-20 University Of Iowa Research Foundation Methodes et produits permettant d'ameliorer des reponses immunitaires a l'aide de compose d'imidazoquinoline
US20040014779A1 (en) 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
CA2467828C (fr) * 2001-11-29 2011-10-04 3M Innovative Properties Company Formulations pharmaceutiques comprenant un modificateur de reponse immunitaire
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
SI1478327T1 (sl) 2002-02-22 2015-08-31 Meda Ab Metoda za zmanjšanje in zdravljenje imunosupresije, inducirane z UV-B
US20030212127A1 (en) * 2002-05-09 2003-11-13 Bradley Pharmaceuticals, Inc. Method of treating actinic keratosis
WO2003101949A2 (fr) 2002-05-29 2003-12-11 3M Innovative Properties Company Procede permettant d'obtenir des imidazo[4,5-c]pyridin-4-amines
AU2003237386A1 (en) 2002-06-07 2003-12-22 3M Innovative Properties Company Ether substituted imidazopyridines
WO2004032829A2 (fr) 2002-08-15 2004-04-22 3M Innovative Properties Company Compositions immunostimulantes et procedes de stimulation d'une reponse immune
US20040043946A1 (en) * 2002-09-03 2004-03-04 Popp Karl F. Topical formulations for treatment of skin disorders
US6818650B2 (en) * 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
AU2003287324A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003287316A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
EP1590348A1 (fr) 2002-12-20 2005-11-02 3M Innovative Properties Company Imidazoquinoleines a substitution aryle/heteroaryle
JP2006512391A (ja) 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
WO2004071459A2 (fr) 2003-02-13 2004-08-26 3M Innovative Properties Company Procedes et compositions associes a des composes modificateurs de reponse immunitaire et recepteur 8 de type toll
EP1599726A4 (fr) 2003-02-27 2009-07-22 3M Innovative Properties Co Modulation selective d'une activite biologique induite par le recepteur tlr
AU2004218349A1 (en) 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
CA2517655A1 (fr) 2003-03-07 2004-09-23 3M Innovative Properties Company 1-amino 1h-imidazoquinolines
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US8426457B2 (en) 2003-03-13 2013-04-23 Medicis Pharmaceutical Corporation Methods of improving skin quality
US7699057B2 (en) 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
US20040191833A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
AU2004244962A1 (en) 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
EP1617845A4 (fr) 2003-04-28 2006-09-20 3M Innovative Properties Co Compositions et methodes d'induction de recepteurs opoides
OA13310A (en) 2003-09-05 2007-04-13 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C.
ES2665342T3 (es) * 2004-03-15 2018-04-25 Meda Ab Formulaciones y métodos para modificadores de la respuesta inmune
WO2008010963A2 (fr) * 2006-07-18 2008-01-24 3M Innovative Properties Company Formules modificatrices de la réponse immunitaire

Also Published As

Publication number Publication date
WO2006099275A3 (fr) 2007-10-25
NI200700239A (es) 2008-06-10
US8354424B2 (en) 2013-01-15
MX2007011112A (es) 2007-11-07
JP2008533148A (ja) 2008-08-21
AU2006223148A1 (en) 2006-09-21
CA2602098A1 (fr) 2006-09-21
BRPI0608011A2 (pt) 2009-11-03
WO2006099275A2 (fr) 2006-09-21
CN101175493A (zh) 2008-05-07
US20080262022A1 (en) 2008-10-23
EP1865957A2 (fr) 2007-12-19
ECSP077736A (es) 2008-01-23
EP1865957A4 (fr) 2009-05-06
RU2007137960A (ru) 2009-04-20
IL185581A0 (en) 2008-08-07
CR9382A (es) 2008-08-26

Similar Documents

Publication Publication Date Title
NO20075278L (no) Fremgangsmate behandling av aktinisk keratose
JP2008533148A5 (fr)
UA109921C2 (uk) ІМІДАЗО[4,5-c]ХІНОЛІН-2-ОН І ЙОГО ЗАСТОСУВАННЯ ЯК ПОДВІЙНОГО ІНГІБІТОРУ PІ3-КІНАЗИ/mTOR
UA98473C2 (ru) СОЛИ И КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 2-МЕТИЛ-2-[4-(3-МЕТИЛ-2-ОКСО-8-ХИНОЛИН-3-ИЛ-2,3-ДИГИДРОИМИДАЗО[4,5-с]ХИНОЛИН-1-ИЛ)ФЕНИЛ]ПРОПИОНИТРИЛА
NO20030398L (no) Estere av 5-aminolevulinsyre som fotosensibiliserende midler i fotokjemoterapi
SV2008002967A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
ATE469674T1 (de) 5-aminolävulinsäure-derivate zur behandlung von akne
NO20060192L (no) Terapeutiske midler anvendelige for behandling av smerte
CL2007002095A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado.
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
CL2007002228A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado.
WO2005009370A3 (fr) Composes de beta-carboline ainsi que leurs analogues et leur utilisation en tant qu'inhibiteurs de proteine kinase-2 activee par proteine kinase activee par des mitogenes
ECSP055575A (es) Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel.
PE20100469A1 (es) Formulaciones de imiquimod
WO2002067988A3 (fr) Utilisation d'inhibiteurs naturels de egfr permettant d'empecher les effets secondaires induits par un traitement par retinoides, des savons, et autres stimuli qui activent le recepteur du facteur de croissance epidermique
ATE539751T1 (de) Verwendung von brimonidine zur behandlung von stress assoziierten zuständen
SI2041133T1 (sl) Imidazo (1,2,a)piridin-2-karboksamidni derivati, njihova priprava in njihova uporaba v terapevtiki
EA201101704A1 (ru) ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
UY31588A1 (es) Derivados de imidazo[1,2-a]piridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica
WO2007098591A3 (fr) Formulation topique pour les ongles
UY31587A1 (es) Derivados de n-heterociclico-imidazo[1,2-a]piridina-2-carboxamidas, su preparacion y su aplicacion en terapéutica.
UY31058A1 (es) Formulaciones de aminoacido n-halogenado con compuestos antiinflamatorios
BR0316132A (pt) Método para estimular o crescimento de cabelo utilizando benzopiranos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application